{ "run": { "id": "cmnr0l2bq01k2p658l4917345", "region": "US", "assetId": "cmnr0l1ul01jsp658j659yt9y", "ticker": "A", "snapshotId": "cmnr0l28301jwp6583o0k3elf", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:06:13.380Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr0l28301jwp6583o0k3elf", "assetId": "cmnr0l1ul01jsp658j659yt9y", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 116.92, "dayLow": 116.26, "volume": 947533, "dayHigh": 118.25, "currency": "USD", "prevClose": 113.88, "week52Low": 96.43, "week52High": 160.27 }, "fundamentals": { "pe": 31.8867102396514, "beta": 1.01618196047755, "epsTTM": 4.59, "fcfTTM": 1026000000, "growth": { "epsYoy": 0.03378378378378366, "revenueYoy": -0.7412204951065055 }, "sector": "Laboratory Analytical Instruments", "margins": { "net": 0.1696329254727475, "gross": null, "operating": 0.196329254727475 }, "website": "http://agilent.com", "industry": null, "pegRatio": 9.43846623093682, "ebitdaTTM": 2021000000, "forwardPe": 24.5983193277311, "marketCap": 26600000000, "totalCash": 1758000000, "totalDebt": 3354000000, "debtEquity": 0.497552291944815, "quickRatio": 1.467770814682184, "revenueTTM": 1798000000, "companyName": "AGILENT TECHNOLOGIES, INC.", "priceToBook": 6.16618305889334, "currentRatio": 2.065801253357207, "dividendYield": 0.00678435191636289, "returnOnAssets": 0.02380394911418091, "returnOnEquity": 0.193294763388221, "analystOpinions": null, "businessSummary": "Agilent Technologies, Inc. is an American global company headquartered in Santa Clara, California, that provides instruments, software, services, and consumables for laboratories. Agilent was established in 1999 as a spin-off from Hewlett-Packard. The resulting initial public offering of Agilent stock was the largest in the history of Silicon Valley at the time. From 1999 to 2014, the company produced optics (LED, laser), semiconductors, EDA software and test and measurement equipment for electronics; that division was spun off to form Keysight. Since then, the company has continued to expand into pharmaceutical, diagnostics & clinical, and academia & government (research) markets.", "enterpriseValue": 43131240000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 18100, "sharesOutstanding": 282602317, "enterpriseToEbitda": 21.34153389411183, "analystTargetMedian": null, "enterpriseToRevenue": 23.98845383759733, "operatingCashflowTTM": 268000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:06:13.252Z" }, "results": [ { "id": "cmnr0l2by01kgp658k4ch7eug", "runId": "cmnr0l2bq01k2p658l4917345", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"A\",\"currency\":\"USD\",\"current_price\":116.92,\"target_price_6m\":122.5,\"target_price_12m\":126.0,\"recommendation\":\"BUY\",\"confidence\":0.55,\"thesis_bullets\":[\"Quality analytical instruments franchise with durable competitive moats\",\"Forward PE of ~24.6x reasonable for high-ROIC compounder\",\"Stock ~27% below 52-week high creates moderate entry opportunity\",\"Slow EPS growth of 3.4% YoY and elevated PEG temper upside enthusiasm\",\"Balance sheet manageable with 2x current ratio and moderate leverage\"],\"key_drivers\":[{\"driver\":\"Pharma/biotech end-market recovery trajectory\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Recurring revenue from consumables and services\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Operating margin expansion toward mid-20s percent\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Sluggish near-term revenue growth weighing on multiples\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Capital deployment via M&A and buybacks\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated PEG ratio of 9.4x signals growth-value disconnect\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"China/emerging market demand normalization\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"AI-driven lab automation adoption expanding TAM\",\"impact\":\"LOW\",\"direction\":\"POS\"}],\"risks\":[\"Prolonged pharma capex downcycle compresses organic growth further\",\"Macro weakness or tariff escalation impacts equipment orders globally\",\"Competitive pressure from Danaher, Thermo Fisher, and Waters\",\"Revenue data anomaly suggests possible structural business change\",\"Multiple contraction if growth fails to reaccelerate in FY26-27\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.23,\"wacc\":0.095,\"terminal_multiple\":22.0},\"scenarios\":{\"bear\":{\"target_price\":97.0,\"prob\":0.2,\"notes\":\"Continued end-market weakness drives further multiple contraction to ~20x forward earnings.\"},\"base\":{\"target_price\":126.0,\"prob\":0.55,\"notes\":\"Gradual pharma recovery supports mid-single-digit EPS growth and ~26x forward PE.\"},\"bull\":{\"target_price\":150.0,\"prob\":0.25,\"notes\":\"Strong end-market rebound and margin expansion re-rate stock toward 30x forward earnings.\"}},\"method_notes\":\"Blended forward PE and EV/EBITDA valuation. Forward EPS ~$4.75 at 26.5x = $126 base. Snapshot revenue TTM ($1.8B) and EBITDA ($2.0B) appear anomalous vs historical ~$6.5B revenue; likely data lag or partial period. Used forward PE as primary anchor. PEG of 9.4x and minimal EPS growth argue for moderate confidence only. 12M return ~7.8% supports BUY but near lower bound. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Prolonged pharma capex downcycle compresses organic growth further", "Macro weakness or tariff escalation impacts equipment orders globally", "Competitive pressure from Danaher, Thermo Fisher, and Waters", "Revenue data anomaly suggests possible structural business change", "Multiple contraction if growth fails to reaccelerate in FY26-27" ], "ticker": "A", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Gradual pharma recovery supports mid-single-digit EPS growth and ~26x forward PE.", "target_price": 126 }, "bear": { "prob": 0.2, "notes": "Continued end-market weakness drives further multiple contraction to ~20x forward earnings.", "target_price": 97 }, "bull": { "prob": 0.25, "notes": "Strong end-market rebound and margin expansion re-rate stock toward 30x forward earnings.", "target_price": 150 } }, "confidence": 0.55, "assumptions": { "wacc": 0.095, "revenue_cagr_3y": 0.04, "terminal_multiple": 22, "ebit_margin_target": 0.23 }, "key_drivers": [ { "driver": "Pharma/biotech end-market recovery trajectory", "impact": "HIGH", "direction": "POS" }, { "driver": "Recurring revenue from consumables and services", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin expansion toward mid-20s percent", "impact": "MED", "direction": "POS" }, { "driver": "Sluggish near-term revenue growth weighing on multiples", "impact": "HIGH", "direction": "NEG" }, { "driver": "Capital deployment via M&A and buybacks", "impact": "MED", "direction": "POS" }, { "driver": "Elevated PEG ratio of 9.4x signals growth-value disconnect", "impact": "MED", "direction": "NEG" }, { "driver": "China/emerging market demand normalization", "impact": "MED", "direction": "NEG" }, { "driver": "AI-driven lab automation adoption expanding TAM", "impact": "LOW", "direction": "POS" } ], "method_notes": "Blended forward PE and EV/EBITDA valuation. Forward EPS ~$4.75 at 26.5x = $126 base. Snapshot revenue TTM ($1.8B) and EBITDA ($2.0B) appear anomalous vs historical ~$6.5B revenue; likely data lag or partial period. Used forward PE as primary anchor. PEG of 9.4x and minimal EPS growth argue for moderate confidence only. 12M return ~7.8% supports BUY but near lower bound. Not investment advice.", "current_price": 116.92, "recommendation": "BUY", "thesis_bullets": [ "Quality analytical instruments franchise with durable competitive moats", "Forward PE of ~24.6x reasonable for high-ROIC compounder", "Stock ~27% below 52-week high creates moderate entry opportunity", "Slow EPS growth of 3.4% YoY and elevated PEG temper upside enthusiasm", "Balance sheet manageable with 2x current ratio and moderate leverage" ], "target_price_6m": 122.5, "target_price_12m": 126 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 42206, "createdAt": "2026-04-09T05:06:13.380Z", "usage": { "inputTokens": 3664, "outputTokens": 1930, "costUsd": 0.06657 } }, { "id": "cmnr0l2by01kjp65825safg47", "runId": "cmnr0l2bq01k2p658l4917345", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"DCF with Terminal Multiple\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"A\",\n \"currency\": \"USD\",\n \"current_price\": 116.92,\n \"target_price_6m\": 118.0,\n \"target_price_12m\": 120.5,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Agilent is a leader in lab instruments with stable market position.\",\n \"Recent revenue decline raises concerns about near-term growth.\",\n \"Margin improvements and cost controls support earnings stability.\",\n \"Valuation appears full relative to current growth projections.\",\n \"Balanced risk-reward suggests holding for clarity on recovery.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Revenue Growth Recovery\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Operating Margin Expansion\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Macroeconomic Lab Spending\", \"impact\": \"HIGH\", \"direction\": \"NEG\" },\n { \"driver\": \"Free Cash Flow Generation\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt and Leverage Levels\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Innovation and R&D Investment\", \"impact\": \"LOW\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive Intensity\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Currency Exchange Rates\", \"impact\": \"LOW\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\n \"Prolonged revenue decline from economic downturns.\",\n \"Increased competition eroding market share.\",\n \"Execution missteps in new product launches.\",\n \"Regulatory changes impacting healthcare sectors.\",\n \"Higher interest rates increasing debt costs.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.2,\n \"wacc\": 0.08,\n \"terminal_multiple\": 20.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 100.0, \"prob\": 0.2, \"notes\": \"Revenue slump continues with margin pressure.\" },\n \"base\": { \"target_price\": 120.0, \"prob\": 0.6, \"notes\": \"Moderate growth and stable margins achieved.\" },\n \"bull\": { \"target_price\": 140.0, \"prob\": 0.2, \"notes\": \"Strong recovery and market share gains.\" }\n },\n \"method_notes\": \"DCF based on 5% revenue growth, 20% EBIT margin, 8% WACC. HOLD due to ~3% upside and mixed evidence. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "DCF with Terminal Multiple", "risks": [ "Prolonged revenue decline from economic downturns.", "Increased competition eroding market share.", "Execution missteps in new product launches.", "Regulatory changes impacting healthcare sectors.", "Higher interest rates increasing debt costs." ], "ticker": "A", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Moderate growth and stable margins achieved.", "target_price": 120 }, "bear": { "prob": 0.2, "notes": "Revenue slump continues with margin pressure.", "target_price": 100 }, "bull": { "prob": 0.2, "notes": "Strong recovery and market share gains.", "target_price": 140 } }, "confidence": 0.6, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.05, "terminal_multiple": 20, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Revenue Growth Recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating Margin Expansion", "impact": "MED", "direction": "POS" }, { "driver": "Macroeconomic Lab Spending", "impact": "HIGH", "direction": "NEG" }, { "driver": "Free Cash Flow Generation", "impact": "MED", "direction": "POS" }, { "driver": "Debt and Leverage Levels", "impact": "MED", "direction": "NEG" }, { "driver": "Innovation and R&D Investment", "impact": "LOW", "direction": "POS" }, { "driver": "Competitive Intensity", "impact": "MED", "direction": "NEG" }, { "driver": "Currency Exchange Rates", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF based on 5% revenue growth, 20% EBIT margin, 8% WACC. HOLD due to ~3% upside and mixed evidence. Not investment advice.", "current_price": 116.92, "recommendation": "HOLD", "thesis_bullets": [ "Agilent is a leader in lab instruments with stable market position.", "Recent revenue decline raises concerns about near-term growth.", "Margin improvements and cost controls support earnings stability.", "Valuation appears full relative to current growth projections.", "Balanced risk-reward suggests holding for clarity on recovery." ], "target_price_6m": 118, "target_price_12m": 120.5 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 353, "createdAt": "2026-04-09T05:06:13.380Z", "usage": { "inputTokens": 2168, "outputTokens": 3774, "costUsd": 0.002192 } }, { "id": "cmnr0l2by01khp658tov5l71w", "runId": "cmnr0l2bq01k2p658l4917345", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"EquityResearch_Agilent\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"A\",\n \"currency\": \"USD\",\n \"current_price\": 116.92,\n \"target_price_6m\": 118.00,\n \"target_price_12m\": 120.00,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Biopharma end-market destocking presents near-term headwinds for instrument sales.\",\n \"Strong recurring revenue from consumables and services provides downside protection.\",\n \"Valuation at ~24x forward P/E appears fair given current growth constraints.\",\n \"China market weakness continues to drag on overall regional performance.\",\n \"Solid free cash flow generation supports ongoing share repurchases and dividends.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Biopharma R&D funding\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"China economic recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Instrument replacement cycle\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Consumables & Services growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Currency fluctuations\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Capital allocation and M&A\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Prolonged downturn in biotech funding and capital expenditures.\",\n \"Intensifying competition in mass spectrometry and chromatography.\",\n \"Geopolitical tensions affecting sales and operations in China.\",\n \"Supply chain disruptions impacting instrument delivery times.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.22,\n \"wacc\": 0.085,\n \"terminal_multiple\": 20.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 95.00,\n \"prob\": 0.25,\n \"notes\": \"Prolonged weakness in instrument replacement cycle and macro headwinds.\"\n },\n \"base\": {\n \"target_price\": 120.00,\n \"prob\": 0.55,\n \"notes\": \"Modest end-market recovery in pharma/biotech, margins hold steady.\"\n },\n \"bull\": {\n \"target_price\": 140.00,\n \"prob\": 0.20,\n \"notes\": \"Strong rebound in China and biopharma funding drives multiple expansion.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of DCF (8.5% WACC) and forward P/E (24x). Snapshot revenue anomaly noted but FCF/EBITDA used for cash flow proxies. Target implies ~2.6% upside, dictating a HOLD recommendation. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "EquityResearch_Agilent", "risks": [ "Prolonged downturn in biotech funding and capital expenditures.", "Intensifying competition in mass spectrometry and chromatography.", "Geopolitical tensions affecting sales and operations in China.", "Supply chain disruptions impacting instrument delivery times." ], "ticker": "A", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Modest end-market recovery in pharma/biotech, margins hold steady.", "target_price": 120 }, "bear": { "prob": 0.25, "notes": "Prolonged weakness in instrument replacement cycle and macro headwinds.", "target_price": 95 }, "bull": { "prob": 0.2, "notes": "Strong rebound in China and biopharma funding drives multiple expansion.", "target_price": 140 } }, "confidence": 0.65, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 20, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Biopharma R&D funding", "impact": "HIGH", "direction": "POS" }, { "driver": "China economic recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Instrument replacement cycle", "impact": "MED", "direction": "NEG" }, { "driver": "Consumables & Services growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Currency fluctuations", "impact": "LOW", "direction": "NEG" }, { "driver": "Capital allocation and M&A", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a blend of DCF (8.5% WACC) and forward P/E (24x). Snapshot revenue anomaly noted but FCF/EBITDA used for cash flow proxies. Target implies ~2.6% upside, dictating a HOLD recommendation. Not investment advice.", "current_price": 116.92, "recommendation": "HOLD", "thesis_bullets": [ "Biopharma end-market destocking presents near-term headwinds for instrument sales.", "Strong recurring revenue from consumables and services provides downside protection.", "Valuation at ~24x forward P/E appears fair given current growth constraints.", "China market weakness continues to drag on overall regional performance.", "Solid free cash flow generation supports ongoing share repurchases and dividends." ], "target_price_6m": 118, "target_price_12m": 120 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 19454, "createdAt": "2026-04-09T05:06:13.380Z", "usage": { "inputTokens": 2517, "outputTokens": 818, "costUsd": 0.01485 } }, { "id": "cmnr0l2by01kfp658u0oe17r7", "runId": "cmnr0l2bq01k2p658l4917345", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"A\",\"currency\":\"USD\",\"current_price\":116.92,\"target_price_6m\":119.5,\"target_price_12m\":121.0,\"recommendation\":\"HOLD\",\"confidence\":0.58,\"thesis_bullets\":[\"Recurring consumables and services support resilient cash generation.\",\"Pharma and diagnostics exposure offers recovery upside if lab spending improves.\",\"Balance sheet and free cash flow provide strategic flexibility.\",\"Valuation still looks full versus muted near-term growth.\",\"Snapshot growth data are inconsistent, limiting conviction and upside.\"],\"key_drivers\":[{\"driver\":\"Recurring consumables mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"CrossLab services growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pharma capex recovery\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Margin discipline\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"China demand softness\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Biotech funding cycle\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Academic/government budgets\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Multiple compression risk\",\"impact\":\"HIGH\",\"direction\":\"NEG\"}],\"risks\":[\"Persistent China and biotech spending weakness\",\"Premium multiple compresses if growth stays slow\",\"FX and order timing volatility\",\"Snapshot revenue and growth data may be anomalous\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.22,\"wacc\":0.085,\"terminal_multiple\":19},\"scenarios\":{\"bear\":{\"target_price\":102,\"prob\":0.25,\"notes\":\"Demand recovery slips and valuation de-rates on weaker orders.\"},\"base\":{\"target_price\":121,\"prob\":0.5,\"notes\":\"Modest end-market recovery and stable margins support limited upside.\"},\"bull\":{\"target_price\":139,\"prob\":0.25,\"notes\":\"Stronger pharma/bioprocess rebound lifts growth and sentiment.\"}},\"method_notes\":\"12M target uses a blended normalized earnings/EV-EBIT view with modest recovery assumptions. Snapshot quote fields were used exactly; snapshot revenue/growth appear inconsistent with Agilent's usual scale, so I weighted margins, cash flow, and business quality more heavily. No sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "OpenAI o3", "risks": [ "Persistent China and biotech spending weakness", "Premium multiple compresses if growth stays slow", "FX and order timing volatility", "Snapshot revenue and growth data may be anomalous" ], "ticker": "A", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Modest end-market recovery and stable margins support limited upside.", "target_price": 121 }, "bear": { "prob": 0.25, "notes": "Demand recovery slips and valuation de-rates on weaker orders.", "target_price": 102 }, "bull": { "prob": 0.25, "notes": "Stronger pharma/bioprocess rebound lifts growth and sentiment.", "target_price": 139 } }, "confidence": 0.58, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 19, "ebit_margin_target": 0.22 }, "key_drivers": [ { "driver": "Recurring consumables mix", "impact": "HIGH", "direction": "POS" }, { "driver": "CrossLab services growth", "impact": "MED", "direction": "POS" }, { "driver": "Pharma capex recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Margin discipline", "impact": "MED", "direction": "POS" }, { "driver": "China demand softness", "impact": "HIGH", "direction": "NEG" }, { "driver": "Biotech funding cycle", "impact": "MED", "direction": "NEG" }, { "driver": "Academic/government budgets", "impact": "MED", "direction": "NEG" }, { "driver": "Multiple compression risk", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "12M target uses a blended normalized earnings/EV-EBIT view with modest recovery assumptions. Snapshot quote fields were used exactly; snapshot revenue/growth appear inconsistent with Agilent's usual scale, so I weighted margins, cash flow, and business quality more heavily. No sell-side targets used; not investment advice.", "current_price": 116.92, "recommendation": "HOLD", "thesis_bullets": [ "Recurring consumables and services support resilient cash generation.", "Pharma and diagnostics exposure offers recovery upside if lab spending improves.", "Balance sheet and free cash flow provide strategic flexibility.", "Valuation still looks full versus muted near-term growth.", "Snapshot growth data are inconsistent, limiting conviction and upside." ], "target_price_6m": 119.5, "target_price_12m": 121 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0c6d15a4b68c04b70069d734d09c8881979ab3b3cbf598c0b5", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 26046, "createdAt": "2026-04-09T05:06:13.380Z", "usage": { "inputTokens": 2436, "outputTokens": 1515, "costUsd": 0.025473 } }, { "id": "cmnr0l2by01kip658grqml6nj", "runId": "cmnr0l2bq01k2p658l4917345", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"A\",\n \"currency\": \"USD\",\n \"current_price\": 116.92,\n \"target_price_6m\": 125.5,\n \"target_price_12m\": 138,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Leader in lab instruments with strong pharma exposure.\",\n \"Solid 17% net margins and healthy cash generation.\",\n \"Sharp revenue YOY decline signals near-term demand risk.\",\n \"Forward PE of 24.6x offers modest expansion potential.\",\n \"Long-term diagnostics growth to drive recovery.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Pharma R&D budgets\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Lab equipment demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Product innovation pipeline\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Economic slowdown effects\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Recurring consumables revenue\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Supply chain cost inflation\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Government research funding\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Valuation multiple expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Prolonged revenue contraction\",\n \"Margin erosion from cost pressures\",\n \"Reduced government research budgets\",\n \"Intense industry competition\",\n \"FX volatility on global sales\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.04,\n \"ebit_margin_target\": 0.21,\n \"wacc\": 0.085,\n \"terminal_multiple\": 22\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 95,\n \"prob\": 0.3,\n \"notes\": \"Persistent demand weakness leads to lower growth.\"\n },\n \"base\": {\n \"target_price\": 138,\n \"prob\": 0.5,\n \"notes\": \"Gradual recovery aligns with historical averages.\"\n },\n \"bull\": {\n \"target_price\": 175,\n \"prob\": 0.2,\n \"notes\": \"Accelerated growth from diagnostics expansion.\"\n }\n },\n \"method_notes\": \"DCF using assumed 4% revenue CAGR, 21% EBIT margin, 8.5% WACC and 22x terminal multiple. BUY reflects ~18% 12M upside despite mixed growth signals. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Prolonged revenue contraction", "Margin erosion from cost pressures", "Reduced government research budgets", "Intense industry competition", "FX volatility on global sales" ], "ticker": "A", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual recovery aligns with historical averages.", "target_price": 138 }, "bear": { "prob": 0.3, "notes": "Persistent demand weakness leads to lower growth.", "target_price": 95 }, "bull": { "prob": 0.2, "notes": "Accelerated growth from diagnostics expansion.", "target_price": 175 } }, "confidence": 0.6, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.04, "terminal_multiple": 22, "ebit_margin_target": 0.21 }, "key_drivers": [ { "driver": "Pharma R&D budgets", "impact": "HIGH", "direction": "POS" }, { "driver": "Lab equipment demand", "impact": "HIGH", "direction": "NEG" }, { "driver": "Product innovation pipeline", "impact": "MED", "direction": "POS" }, { "driver": "Economic slowdown effects", "impact": "MED", "direction": "NEG" }, { "driver": "Recurring consumables revenue", "impact": "HIGH", "direction": "POS" }, { "driver": "Supply chain cost inflation", "impact": "MED", "direction": "NEG" }, { "driver": "Government research funding", "impact": "MED", "direction": "POS" }, { "driver": "Valuation multiple expansion", "impact": "MED", "direction": "POS" } ], "method_notes": "DCF using assumed 4% revenue CAGR, 21% EBIT margin, 8.5% WACC and 22x terminal multiple. BUY reflects ~18% 12M upside despite mixed growth signals. Not investment advice.", "current_price": 116.92, "recommendation": "BUY", "thesis_bullets": [ "Leader in lab instruments with strong pharma exposure.", "Solid 17% net margins and healthy cash generation.", "Sharp revenue YOY decline signals near-term demand risk.", "Forward PE of 24.6x offers modest expansion potential.", "Long-term diagnostics growth to drive recovery." ], "target_price_6m": 125.5, "target_price_12m": 138 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "7b8259f7-3624-96a7-9eac-15a396eae3d0", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 28287, "createdAt": "2026-04-09T05:06:13.380Z", "usage": { "inputTokens": 2769, "outputTokens": 3646, "costUsd": 0.062997 } } ] } }